Evaluation of chalcones - A flavonoid subclass, for, their anxiolytic effects in rats using elevated plus maze and open field behaviour tests

Fundamental and Clinical Pharmacology

Volumn 22, Issue 6, 2008, Pages 673-681

  Jamal, Huma ^a,b   Ansari, Wajid Hussain ^a   Rizvi, Shamim Jahan ^b  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Anxiety; Chalcones; Elevated plus maze; Muscle relaxant; Open field behaviour

Indexed keywords

1 (4 CHLOROPHENYL) 3 (4 METHOXYPHENYL) 3 (CARBOXYMETHYLTHIO)PROPAN 1 ONE; 1,3 BIS(4 CHLOROPHENYL) 3 (CARBOXYMETHYLTHIO)PROPAN 1 ONE; 2' HYDROXY 3,4 DIMETHOXYCHALCONE; 2',2 DIHYDROXYCHALCONE; 4' CHLORO 4 METHOXYCHALCONE; 4',4 DICHLOROCHALCONE; BUTEIN; CHALCONE DERIVATIVE; DIAZEPAM; ISOLIQUIRITIGENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; GRIP STRENGTH; MALE; MAZE TEST; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; ROTAROD TEST; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; CHALCONES; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; MOLECULAR STRUCTURE; MOTOR ACTIVITY; MUSCLE STRENGTH; PSYCHOMOTOR PERFORMANCE; RATS; ROTAROD PERFORMANCE TEST; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57049108624     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00639.x     Document Type: Article

References (52)

1. Pratt J.A. The neuroanatomical basis of anxiety. Pharmacol. Ther. (1992) 55 149 181.
2. Bravo L. Polyphenols: chemistry, dietary sources, metabolism and nutritional significance. Nutr. Rev. (1998) 56 317 333.
3. Wolfman C., Viola H., Paladini A.C., Dajas F., Medina J.H. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from passiflora coerulea. Pharmacol. Biochem. Behav. (1994) 47 1 4.
4. Ai J., Dekermendjian K., Wang X., Nielson M., Witt M.R. 6 - Methylflavone, a benzodiazepine receptor ligand with antagonistic properties on rat brain and human recombinant GABAA receptor in vitro. Drug Dev. Res. (1997) 41 99 108.
5. Anto R.J., Sukumaran K., Kuttan G., Rao M.N.A., Subbaraju V., Kuttan R. Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Lett. (1995) 97 33 37.
6. Chin C., Nagaratnam P. Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. Cancer Lett. (1994) 82 65 72.
7. Tomas - Barberan F.A., Clifford M.N. Review. Flavanones, chalcones, and dihydrochalcones - nature, occurance and dietary burden. J. Sci. Food Agric. (2000) 80 1073 1080.
8. Bohm B.A. Chalcones and aurones, in : Dey P.M., Harborne J.B. (Eds Plant phenols, Academic Press, London, 1989, pp. 237 287.
9. Dhar D.N. The chemistry of chalcones and related compounds, Wiley, New York, 1981.
10. Wegener J.W., Nawarth H. Cardiac effects of isoliquiritigenin. Eur. J. Pharmacol. (1997) 326 37 44.
11. Yang E.B., Zhang K., Cheng L.Y., Mack P. Butein, a specific protein tyrosine kinase inhibitor. Biochem. Res. Commun. (1998) 245 435 438.
12. Kim N.Y., Pae H.O., Oh G.S. et al. Butein a plant polyphenol, induces apoptosis concomitant Bcl-2 expression and increased Bax expression in HL-60 cells. Pharmacol. Toxicol. (2001) 88 261 266.
13. Dimmock J.R., Elias D.W., Beazely M.A., Kandepu N.M. Bioactivities of chalcones. Curr. Med. Chem. (1996) 6 1125 1149.
14. Severi F., Costantino L., Benvenuti S., Vampa G., Mucci A. Synthesis and description of chalcone-like compounds, inhibitors of aldose reductase. Med. Chem. Res. (1996) 6 128 136.
15. Sogawa S., Nihro Y., Ueda H. et al. 3, 4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors. J. Med. Chem. (1993) 36 3904 3909.
16. Hsieh H.K., Lee T.H., Wang J.P., Wang J.J., Lin C.N. Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm. Res. (1998) 15 39 46.
17. Hsieh H.K., Tsao L.T., Wang J.P., Lin C.N. Synthesis and anti-inflammatory effect of chalcones. J. Pharm. Pharmacol. (2000) 52 163 170.
18. Davey W., Gwilt J.R. Chalcones and related compounds. Part I. Preparation of nitro-, amino-, and halogeno-chalcones. J. Chem. Soc. (1957) 1 1008 1019.
19. Levai A. Synthesis of carboxylic acid derivatives of dihydrochalcones. Monatsh. Chem (1991) 122 127 129.
20. Wei A.N., Yang J., Ying A.O. Metallothionein indicates cardioprotection of isoliquiritigenin against ischemia - reperfusion through JAK2/STAT3 activation. Acta Pharmacol Sin (2006) 27 1431 1437.
21. Chan C., Yang J. Protective effects of isoliquiritigenin in transient middle cerebral artery occlusion - induced focal cerebral ischemia in rats. Pharmacol. Res. (2006) 53 303 309.
22. Brown S., Griffiths L.A. Metabolism and excretion of butein, 2′,3,4-trihydroxychalcone, 3-o-methylbutein, 4-o-methylbutein and 2′,4′,4-trihydroxychalcone in rat. Xenobiotica (1983) 13 669 682.
23. Moran P.M., Higgins L.S., Cordel B., Moser P.C. Age related learning deficits in transgenic mice expressing the 721- amino acid isoform of human beta - amyloid precursor protein. Acad. Natl. Acad. Sci. USA (1995) 92 5341 5345.
24. Pellow S., Chopin P., File S.E., Briley M. Validation of open closed arm entries in an elevated plus maze as a measure of anxiety in the rat. J. Neurosci. Methods (1985) 14 149 167.
25. Holland H.C., Gupta B.D. Some correlated measures of activity and reactivity in two strains of selectively bred for differences in the acquisition of a conditioned avoidance response. Anim. Behav. (1996) 14 574 580.
26. Hall C.S. Emotional behavior in the rat. I. Defecation and urination as measures of individual differences in emotionality. J. Comp. Physiol. Psychol. (1971) 20 169 171.
27. Hoggs S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. (1996) 54 21 30.
28. Rodgers R.J. Animal models of anxiety: where next? Behav. Pharmacol. (1997) 8 477 496.
29. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (1987) 92 180 185.
30. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti anxiety agents. Psychopharmacologia (1971) 21 1 7.
31. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus - maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. (1986) 24 525 529.
32. Winslow J.T., Insel T.R. Infant rat separation is a sensitve test for novel anxiolytics. Prog. Neuropsychopharmacol. Biol. Psychiatry (1991) 15 745 757.
33. Weiss S.M., Wadsworth G., Fletcher A., Dourish C.T. Utility of ethological analysis to overcome locomotor confounds in elevated maze models of anxiety. Neurosci. Biobehav. Rev. (1998) 23 265 271.
34. Helton D R., Berger J.E., Czachura J.F., Rasmussen K., Kalman M.J. Central nervous system characterization of the new cholecystokinin B antagonist LY 288513. Pharmacol. Biochem. Behav. (1996) 53 493 502.
35. Woods J.H., Winger G. Current benzodiazepine tissue. Psychopharmacology (1995) 118 107 115.
36. Charney D.S., Mihie S.I., Harris A.D. Hypnotics and sedatives, in : Hardman J.G., Limbird L.E. (Eds Goodman's and Gilman's. The pharmacological basis of therapeutics, 10th edn, The McGraw Hill Companies Inc., USA, 2001, pp. 399 428.
37. Davis M., Rainnie D., Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci. (1994) 17 208 214.
38. Watson B., Hughes A.L. Pharmacological treatment of addiction. Psychiatry (2007) 6 309 312.
39. Boulenger J.P. Treatment of generalized anxiety: new pharmacological approaches. Encephale (1995) 21 459 466.
40. Tatarczynska E., Klodzinska A., Stachowicz K., Chojnacka W.E. Effect of selective 5-HT1 B receptor agonist and antagonists in animal models of anxiety and depression. Behav. Pharmacol. (2004) 15 523 534.
41. Nishikawa T., Scatton B. Evidence for a GABAergic inhibitory influence on serotonergic neurons originating from the dorsal raphe. Brain Res. (1983) 279 325 329.
42. Nishikawa T., Scatton B. Inhibitory influence of GABA on central serotonergic transmission. Involvement of the habenuloraphe pathways in the GABAergic inhibition of ascending cerebral serotonergic neurons. Brain Res. (1985) 331 81 90.
43. Bhattacharya S.K., Chakrabarti A., Sandler M., Glover V. Rat brain MAO-A & B inhibitory (tribulin) activity during withdrawl activity. Neurosci. Lett. (1995) 199 103 106.
44. Bhattacharya S.K., Chakrabarti A., Sandler M., Glover V. Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A & B inhibitory (tribulin) activity. Ind. J. Exp. Biol. (1996) 34 1190 1193.
45. Kong L.D., Zhang Y., Pan X., Tang R.X., Cheng C.H. Inhibition of xanthine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchatia chinesis. Cell. Mol. Life Sci. (2000) 57 500 505.
46. Tan R.X., Meng J.C., Hostettman K. Phytochemical investigation of some traditional Chinese medicines and endophyte cultures. Pharmaceut. Biol. Suppl. (2000) 38 25 32.
47. Zarrindast M.R., Valizadegan F., Rostami P., Rezayof A. The effects of histaminergic agents in the elevated plus- maze test of anxiety. Pharmacol. Biochem. Behav. (2006) 85 500 506.
48. Mitsutoshi Y., Yasushi I., Atsushi I., Hiroshi S., Hisashi K., Yuji M. Effects of drugs acting as histamine releasers or histamine receptor blockers on an experimental anxiety model in mice. Pharmacol. Biochem. Behav. (2000) 67 145 150.
49. 2- receptor antagonist ranitidine on depression and anxiety in duodenal ulcer patients. Postgrad. Med. J. (1984) 60 353 355.
50. Kim D.C., Choi S.Y., Kim K.T. Isoliquiritigenin selectively inhibits H(2) histamine receptor. Mol. Pharmacol. (2006) 70 493 500.
51. Masur J., Martz R.M.W., Carlini E.A. Effects of acute and chronic administration of Cannabis Sativa and (-) Δω- trans- tetrahydrocannabinol on behavior of rats in open field arena. Psychopharmacology (1971) 19 338 397.
52. Ozturk Y., Aydini S., Beis R., Baser K.H.C. Effect of Hypericum perforatum L. and Hypericum calycinum L. extracts on the central nervous in mice. Phytomedicine (1996) 3 139 146.